Skip to main contentSkip to navigation

KYMR Stock: Kymera Therapeutics, Inc. Stock Price, Analysis & Insights

Get live KYMR stock price $78.89, comprehensive Kymera Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time KYMR stock data and investment insights.

78.89
2.13%Today
KYMRKymera Therapeutics, Inc. • NASDAQ Global Market • Healthcare
Market Cap
6.49B
Volume
549.37K
52W High
103.00
52W Low
28.06

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It enga...

Company Information

CEO
Nello Mainolfi
Sector
Healthcare
Industry
Biotechnology
Employees
208

Contact Information

Address
200 Arsenal Yards Boulevard
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 2.06)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Kymera Therapeutics, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Kymera Therapeutics, Inc.
  • Investors should consider how Kymera Therapeutics, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

6.49B

P/E Ratio (TTM)

-22.04

Beta

2.06

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

Related Healthcare Stocks

Compare KYMR with:

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.